AGP Picks
View all

FBB Biomed files patent on RNA signals in the dark genome

Nov. 5, 2026
By AI, Created 21:07 UTC, Nov 05, 2026, AGP -

FBB Biomed filed a provisional U.S. patent application on Nov. 4, 2026, covering long non-coding RNA transcripts from the largely uncharacterized 47% of the human genome. The company says the approach could improve blood-based diagnostics and help drug developers find and track trial participants with silent inflammation.

Why it matters: - FBB Biomed is aiming at regulatory RNA signals that sit upstream of inflammation, which could give drug developers an earlier read on disease biology than conventional protein-based tests. - The company says the approach could help identify trial participants with “silent inflammation” — significant inflammation without obvious symptoms. - The planned use case is broader than diagnostics. FBB Biomed expects the patent filing to support blood-based measurements for monitoring, stratifying, and selecting clinical-trial participants.

What happened: - FBB Biomed filed a provisional patent application with the U.S. Patent and Trademark Office on Nov. 4, 2026. - The application covers long non-coding RNA, or lncRNA, transcripts from the largely uncharacterized 47% of the human genome. - The filing covers characterization and assay of these transcript loci, plus diagnostic and therapeutic applications. - The company announced the filing on Nov. 5, 2026, from Coralville, Iowa.

The details: - The human genome has about 3 billion DNA letters. - About 1.5% of the genome codes for protein. - Roughly half of the genome is made up of repeats. - The remaining 47% is largely unique, non-coding sequence. - FBB Biomed says that region produces tens of thousands of RNA transcripts, most with no known function. - Many of those transcripts help regulate when, where and how strongly genes turn on. - FBB Biomed says its RNA Systems Intelligence platform quantifies more blood RNA transcripts than conventional methods, including previously uncharacterized transcripts from the non-coding genome. - The company’s blood RNA library spans neurodegenerative, autoimmune, cancer and post-infectious conditions, plus healthy controls. - FBB Biomed says conventional inflammation markers such as high-sensitivity C-reactive protein, or hsCRP, may miss participants with silent inflammation. - The platform is designed to give trial sponsors a per-participant readout from a standard blood draw. - The company listed three core trial uses: longitudinal monitoring across serial visits, participant selection based on RNA profiles, and early target-engagement readouts. - FBB Biomed intends to offer the platform as a measurement service inside sponsor protocols and to license specific targets by field of use. - “Reading that other half lets us see inflammation further upstream and turns dark matter into something you can measure,” Howard Urnovitz, PhD, CEO of FBB Biomed, said. - Urnovitz said the platform could help developers see which trial participants are silently inflamed and whether a drug is reaching them from a single blood draw.

Between the lines: - The filing signals an effort to turn a largely unstudied part of the genome into a commercial testing and drug-development platform. - The emphasis on upstream biology suggests FBB Biomed is positioning itself against standard inflammation tests that may capture the cascade too late. - The patent claim also gives the company a potential moat around assays and targets tied to its RNA interpretation system, though a provisional filing does not guarantee a granted patent.

What's next: - FBB Biomed plans to use the platform inside clinical-trial protocols with drug developers. - The company also plans to license specific targets by field of use. - Any future patent protection depends on whether the provisional filing leads to issued claims. - FBB Biomed says the work will continue to support monitoring and stratification in clinical trials, especially in inflammation-related programs.

The bottom line: - FBB Biomed is betting that the “dark genome” can become a measurable source of biomarkers and drug targets for inflammation-focused trials. The provisional patent is the first step, not a guarantee of protection or commercial adoption.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Iowa Business Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Iowa Business Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.